Literature DB >> 16955468

Analysis of genetic abnormalities provides insights into genetic evolution of hyperdiploid myeloma.

Wee J Chng1, Rhett P Ketterling, Rafael Fonseca.   

Abstract

Aneuploidy is ubiquitous in human cancer and is seen as whole chromosome gains and losses, unbalanced translocations and inversions, duplications, deletions and loss of heterozygosity. Within this complexity, some subgroups of aneuploid tumors emerge as distinct biological and clinical entities. Hyperdiploid myeloma (H-MM), characterized by hyperdiploid chromosome numbers because of nonrandom trisomies, is one such example. We undertook a comprehensive survey of the karyotypes of a large number of H-MM (n = 469) to describe fully genomic instability in these tumors, to dissect pathways of genetic evolution, and identify distinct subgroups based on their genetic changes. While selective pressure apparently favors the emergence of clones with gains of chromosomes 3, 5, 7, 9, 11, 15, 19, and 21, a background of ongoing genomic instability results in gains of other chromosomes, albeit at a much lower prevalence. A deduced temporal analysis of these karyotypes indicates that selected gains are early events. Other events occurring later in the course of the disease include secondary chromosome translocations and monosomies. The development of these genetic aberrations is thus highly ordered and undoubtedly of biological relevance. Within this framework, we propose a model of genetic evolution in H-MM. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2006        PMID: 16955468     DOI: 10.1002/gcc.20375

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  15 in total

1.  Cell lines of hyperdiploid myeloma, are we there yet?

Authors:  Wee J Chng; Rafael Fonseca
Journal:  Br J Haematol       Date:  2007-11-19       Impact factor: 6.998

2.  Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma.

Authors:  S Kumar; L Zhang; A Dispenzieri; S Van Wier; J A Katzmann; M Snyder; E Blood; R DeGoey; K Henderson; R A Kyle; A R Bradwell; P R Greipp; S V Rajkumar; R Fonseca
Journal:  Leukemia       Date:  2010-06-03       Impact factor: 11.528

3.  Conventional Cytogenetics and Interphase Fluorescence In Situ Hybridization Results in Multiple Myeloma: A Turkey Laboratory Analysis of 381 Cases.

Authors:  Cigdem Aydin; Turgay Ulas; Ceren Hangul; Orhan Kemal Yucel; Utku Iltar; Ozan Salim; Deniz Ekinci; Sibel Berker Karauzum
Journal:  Indian J Hematol Blood Transfus       Date:  2019-10-25       Impact factor: 0.900

Review 4.  Latest advances and current challenges in the treatment of multiple myeloma.

Authors:  Anuj Mahindra; Jacob Laubach; Noopur Raje; Nikhil Munshi; Paul G Richardson; Kenneth Anderson
Journal:  Nat Rev Clin Oncol       Date:  2012-02-21       Impact factor: 66.675

5.  Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics.

Authors:  Shaji Kumar; Rafael Fonseca; Rhett P Ketterling; Angela Dispenzieri; Martha Q Lacy; Morie A Gertz; Suzanne R Hayman; Francis K Buadi; David Dingli; Ryan A Knudson; Alexandra Greenberg; Stephen J Russell; Steven R Zeldenrust; John A Lust; Robert A Kyle; Leif Bergsagel; S Vincent Rajkumar
Journal:  Blood       Date:  2012-01-10       Impact factor: 22.113

6.  An adaptive trial design to optimize dose-schedule regimes with delayed outcomes.

Authors:  Ruitao Lin; Peter F Thall; Ying Yuan
Journal:  Biometrics       Date:  2019-09-19       Impact factor: 2.571

Review 7.  Multiple Myeloma: Molecular Pathogenesis and Disease Evolution.

Authors:  Michael Heider; Katharina Nickel; Marion Högner; Florian Bassermann
Journal:  Oncol Res Treat       Date:  2021-11-08       Impact factor: 2.825

8.  Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors.

Authors:  Ana Gabrea; Maria Luisa Martelli; Ying Qi; Anna Roschke; Bart Barlogie; John D Shaughnessy; Jeffrey R Sawyer; W Michael Kuehl
Journal:  Genes Chromosomes Cancer       Date:  2008-07       Impact factor: 5.006

9.  Prognostic impact of hyperdiploidy in multiple myeloma patients with high-risk cytogenetics: a pilot study in China.

Authors:  Jiangang Mei; Yongping Zhai; Hanqing Li; Feng Li; Xiaogang Zhou; Ping Song; Qian Zhao; Yaping Yu; Zhiming An; Liping Wang
Journal:  J Cancer Res Clin Oncol       Date:  2018-08-24       Impact factor: 4.553

10.  High expression of BCL3 in human myeloma cells is associated with increased proliferation and inferior prognosis.

Authors:  Anne-Tove Brenne; Unn-Merete Fagerli; John D Shaughnessy; Thea Kristin Våtsveen; Torstein Baade Rø; Hanne Hella; Fenghuang Zhan; Bart Barlogie; Anders Sundan; Magne Børset; Anders Waage
Journal:  Eur J Haematol       Date:  2009-01-13       Impact factor: 2.997

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.